Free fatty acid receptor 1: Difference between revisions
CSV import |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 31: | Line 31: | ||
{{biochemistry-stub}} | {{biochemistry-stub}} | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
Latest revision as of 17:24, 18 March 2025
Free fatty acid receptor 1 (FFAR1), also known as G protein-coupled receptor 40 (GPR40), is a protein that in humans is encoded by the FFAR1 gene. It is a member of the G protein-coupled receptor family and plays a significant role in the regulation of glucose homeostasis and insulin secretion.
Function[edit]
FFAR1 is a receptor for medium and long chain free fatty acids (FFAs). It is mainly expressed in pancreatic beta cells and to a lesser extent in the brain, where it mediates the potentiation of glucose-stimulated insulin secretion. FFAR1 is involved in the taste perception of fatty acids, and it also mediates the taste of fat.
Clinical significance[edit]
FFAR1 has been identified as a potential therapeutic target for the treatment of type 2 diabetes. Activation of FFAR1 by FFAs enhances insulin secretion from pancreatic beta cells only in the presence of elevated glucose levels. This glucose-dependent insulinotropic effect has led to the development of synthetic FFAR1 agonists for the treatment of type 2 diabetes.
Pharmacology[edit]
Several synthetic FFAR1 agonists have been developed for the treatment of type 2 diabetes. These include TAK-875 (Fasiglifam), a selective FFAR1 agonist that has been shown in clinical trials to improve glycemic control in patients with type 2 diabetes.
See also[edit]
References[edit]
<references group="" responsive="1"></references>
This GPCR-related article is a stub. You can help WikiMD by expanding it.

This article is a biochemistry stub. You can help WikiMD by expanding it!
